Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Rating of “Hold” by Brokerages

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have been given an average recommendation of “Hold” by the nine brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $5.25.

MRVI has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Maravai LifeSciences in a research report on Tuesday, October 14th. Wells Fargo & Company upped their price objective on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the stock an “overweight” rating in a research note on Monday, December 15th.

Insider Buying and Selling

In related news, CEO Bernd Brust bought 216,212 shares of the company’s stock in a transaction on Thursday, November 13th. The shares were acquired at an average price of $3.25 per share, with a total value of $702,689.00. Following the transaction, the chief executive officer owned 466,771 shares of the company’s stock, valued at $1,517,005.75. The trade was a 86.29% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Gregory T. Lucier purchased 51,472 shares of the business’s stock in a transaction dated Friday, December 5th. The stock was bought at an average price of $3.70 per share, for a total transaction of $190,446.40. Following the completion of the acquisition, the director directly owned 106,595 shares in the company, valued at approximately $394,401.50. This trade represents a 93.38% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have bought 566,771 shares of company stock worth $1,880,244. Insiders own 2.11% of the company’s stock.

Institutional Investors Weigh In On Maravai LifeSciences

A number of hedge funds have recently made changes to their positions in MRVI. Monaco Asset Management SAM grew its stake in Maravai LifeSciences by 315.0% in the third quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company’s stock valued at $10,494,000 after purchasing an additional 2,775,372 shares during the last quarter. Philosophy Capital Management LLC bought a new stake in shares of Maravai LifeSciences in the 1st quarter valued at about $5,731,000. Tejara Capital Ltd grew its position in shares of Maravai LifeSciences by 257.8% in the 2nd quarter. Tejara Capital Ltd now owns 1,941,449 shares of the company’s stock worth $4,679,000 after buying an additional 1,398,900 shares during the last quarter. 12 West Capital Management LP raised its stake in shares of Maravai LifeSciences by 8.0% during the 1st quarter. 12 West Capital Management LP now owns 12,521,335 shares of the company’s stock worth $27,672,000 after acquiring an additional 930,000 shares in the last quarter. Finally, First Pacific Advisors LP purchased a new stake in Maravai LifeSciences during the second quarter valued at approximately $1,787,000. 50.25% of the stock is currently owned by hedge funds and other institutional investors.

Maravai LifeSciences Trading Up 4.6%

MRVI stock opened at $3.40 on Friday. Maravai LifeSciences has a 12 month low of $1.66 and a 12 month high of $6.21. The firm’s 50-day moving average is $3.39 and its 200 day moving average is $2.92. The company has a market capitalization of $869.41 million, a PE ratio of -4.05 and a beta of 0.33. The company has a debt-to-equity ratio of 0.74, a current ratio of 5.29 and a quick ratio of 4.56.

Maravai LifeSciences (NASDAQ:MRVI) last issued its earnings results on Thursday, November 6th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). The company had revenue of $41.63 million during the quarter, compared to the consensus estimate of $49.02 million. Maravai LifeSciences had a negative return on equity of 22.42% and a negative net margin of 62.88%. On average, research analysts anticipate that Maravai LifeSciences will post -0.24 EPS for the current year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.